MAP2K7 and metastatic melanoma: The presence of the B-Raf proto-oncogene serine/threonine kinase (BRAF) V600 mutation in 40%–50% of melanomas and its role as a predictive factor of response to BRAF inhibitors in combination with mitogen-activated protein kinase kinase (MEK) inhibitors were crucial in establishing an appropriate therapeutic management algorithm for metastatic melanomas [3].